Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
By Staff Reporters
***
***
Eli Lilly said its weight loss drugs can prevent diabetes
Taking Zepbound or Mounjaro can cut the risk of developing Type 2 diabetes by 94% in overweight and pre-diabetic patients, according to a new study from the US drug maker.
The drugs, similar to Ozempic and Wegovy from rival company Novo Nordisk, cost more than $1,000 a month and have fueled Eli Lilly’s stock since hitting the market in recent years. The pharma giant sold ~$3.1 billion of Mounjaro last quarter, up from $980 million in the same period last year.
COMMENTS APPRECIATED
Thank You
***
***
Share this:
Filed under: Drugs and Pharma, Ethics, Health Insurance, Investing, Research & Development | Tagged: diabetes, Eli Lilly, Mounjaro, Novo Nordisk, Zepbound |
The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants 
Leave a comment